Clinical Trial Update: Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab for chronic inflammatory demyelinating polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Status: WITHDRAWN